IKT - Cash Flow Statement - Inhibikase Therapeutics, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016
OPERATING CASH FLOW
Net Income	(27.5)	(19.0)	(18.1)	(14.8)	(2.8)	(5.7)	(2.2)	(0.4)	(0.6)
Depreciation & Amortization	26.3 K	0.2	6.72 K	0	0	0	0	0	0
Deferred Income Tax	0	0	0	0	0	0	0	0	0
Stock Based Compensation	8.1	0.5	0.5	1.5	0.6	1.4	0.6	0.3	0.3
Other Operating Activities	0	31.5 K	67 K	0.7	1.6	2.3	0.7	0.5	95.7 K
Change in Working Capital	0.2	0.2	0.2	(1.8)	(0.5)	1.6	1.5	32.8 K	0.2
Cash From Operations	(19.1)	(18.1)	(17.4)	(14.3)	(1.1)	(0.3)	0.7	(0.1)	29.6 K
INVESTING CASH FLOW
Capital Expenditures	0	14.2 K	(0.2)	0	0	0	0	0	0
Other Items	(37.0)	11.7	(15.8)	0	0	0	87.1 K	0	0
Cash From Investing Activities	(37.0)	11.7	(16.0)	0	0	0	87.1 K	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	0	0	0	0
Total Debt Repaid	0	0	(0.2)	42.5 K	0.3	22.8 K	26.3 K	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Other Financing Activities	0	(0.1)	0	848	0	0	(1.6)	0.1	23.8 K
Cash From Financing Activities	103.5	8.4	(0.2)	41.1	15.1	22.8 K	(0.4)	0.1	23.8 K
CHANGE IN CASH
Net Change In Cash	47.3	2.0	(33.6)	26.8	13.9	(0.4)	0.4	4.63 K	53.3 K
FREE CASH FLOW
Free Cash Flow	(19.1)	(18.1)	(17.6)	(14.3)	(1.1)	(0.3)	0.7	(0.1)	29.6 K

Free